Publicaciones científicas

Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting

22-mar-2024 | Revista: Clinical Lymphoma, Myeloma & Leukemia

Noopur S Raje  1 , Adam D Cohen  2 , Krina K Patel  3 , Niels W C J van de Donk  4 , Joshua Richter  5 , Jesus San-Miguel  6


Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies.

Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies.

CITA DEL ARTÍCULO  Clin Lymphoma Myeloma Leuk. 2024 Mar 22:S2152-2650(24)00112-5. doi: 10.1016/j.clml.2024.03.005